Display options
Cite
Chang GR, Hou PH, Yang WC, et al. Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice. Pharmaceuticals (Basel). 2021;14(3)doi: 10.3390/ph14030267.
Chang, G. R., Hou, P. H., Yang, W. C., Wang, C. M., Fan, P. S., Liao, H. J., & Chen, T. P. (2021). Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice. Pharmaceuticals (Basel, Switzerland), 14(3), . https://doi.org/10.3390/ph14030267
Chang, Geng-Ruei, et al. "Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice." Pharmaceuticals (Basel, Switzerland) vol. 14,3 (2021). doi: https://doi.org/10.3390/ph14030267
Chang GR, Hou PH, Yang WC, Wang CM, Fan PS, Liao HJ, Chen TP. Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice. Pharmaceuticals (Basel). 2021 Mar 16;14(3). doi: 10.3390/ph14030267. PMID: 33809508; PMCID: PMC8001117.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Mar 16;14(3). doi: 10.3390/ph14030267.

Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice.

Pharmaceuticals (Basel, Switzerland)

Geng-Ruei Chang, Po-Hsun Hou, Wei-Cheng Yang, Chao-Min Wang, Pei-Shan Fan, Huei-Jyuan Liao, To-Pang Chen

Affiliations

  1. Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan.
  2. Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan.
  3. Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan.
  4. School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan.
  5. Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan.

PMID: 33809508 PMCID: PMC8001117 DOI: 10.3390/ph14030267

Abstract

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for eight weeks. We noted that the treated mice had higher body, kidney, liver, retroperitoneal, and epididymal white adipose tissue weights; serum and liver triglyceride, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine levels; daily food efficiency; and liver lipid regulation marker expression. They also demonstrated exacerbated insulin resistance and glucose intolerance with lower Akt phosphorylation, GLUT4 expression, and renal damage as well as higher reactive oxygen species and interleukin 1 and lower catalase, superoxide dismutase, and glutathione peroxidase levels. The treated mice had a net-negative Cr balance due to increased urinary excretion, leading to Cr mobilization, delaying hyperglycemia recovery. Furthermore, they had considerably increased fatty liver scores, paralleling increases in adiponectin, FASN, PNPLA3,

Keywords: chromium; doxepin; fatty liver disease; glucose intolerance; obesity; renal impairment

References

  1. Cochrane Database Syst Rev. 2013 Jun 18;(6):CD002317 - PubMed
  2. Methods Find Exp Clin Pharmacol. 1992 Jan-Feb;14(1):61-71 - PubMed
  3. Basic Clin Pharmacol Toxicol. 2009 Sep;105(3):188-98 - PubMed
  4. J Clin Invest. 2003 Jan;111(2):197-208 - PubMed
  5. Biochem Biophys Res Commun. 2020 Aug 20;529(2):474-479 - PubMed
  6. Int J Clin Pharm. 2011 Jun;33(3):484-92 - PubMed
  7. J Gen Intern Med. 2006 Nov;21(11):1133-7 - PubMed
  8. JPEN J Parenter Enteral Nutr. 2008 Sep-Oct;32(5):578-81 - PubMed
  9. J Cell Mol Med. 2020 Jan;24(2):1541-1552 - PubMed
  10. Eur J Cancer Care (Engl). 2006 May;15(2):138-45 - PubMed
  11. Genomics. 2008 Dec;92(6):436-45 - PubMed
  12. Clin Sci (Lond). 1991 Apr;80(4):373-84 - PubMed
  13. CNS Drugs. 2017 Jun;31(6):483-493 - PubMed
  14. FASEB J. 2016 Jan;30(1):324-35 - PubMed
  15. Postgrad Med. 2013 Sep;125(5):117-29 - PubMed
  16. Curr Gastroenterol Rep. 2016 Jan;18(1):2 - PubMed
  17. Naunyn Schmiedebergs Arch Pharmacol. 1974;285(1):99-102 - PubMed
  18. Sleep. 2011 Oct 01;34(10):1433-42 - PubMed
  19. Expert Opin Investig Drugs. 2020 Feb;29(2):197-204 - PubMed
  20. Curr Opin Psychiatry. 2013 Jan;26(1):60-5 - PubMed
  21. Liver Transpl. 2019 Jul;25(7):1074-1090 - PubMed
  22. J Clin Invest. 2019 Oct 1;129(10):4001-4008 - PubMed
  23. BMJ Open. 2018 May 24;8(5):e019868 - PubMed
  24. Can J Psychiatry. 2004 Jan;49(1):74-5 - PubMed
  25. Iran J Basic Med Sci. 2018 May;21(5):495-501 - PubMed
  26. Diabetes. 2013 Mar;62(3):721-31 - PubMed
  27. J Clin Diagn Res. 2015 Nov;9(11):OC05-8 - PubMed
  28. Animals (Basel). 2020 Aug 14;10(8): - PubMed
  29. Gen Hosp Psychiatry. 2019 May - Jun;58:1-6 - PubMed
  30. Horm Mol Biol Clin Investig. 2018 Jan 10;36(1): - PubMed
  31. Am J Physiol Renal Physiol. 2011 Feb;300(2):F301-10 - PubMed
  32. Hum Cell. 2020 Jul;33(3):502-511 - PubMed
  33. Biomed Res Int. 2018 Jul 3;2018:8249563 - PubMed
  34. Am J Psychiatry. 2014 Apr;171(4):404-15 - PubMed
  35. Brain Res. 2001 Dec 27;923(1-2):82-90 - PubMed
  36. Biol Trace Elem Res. 2021 Feb;199(2):622-632 - PubMed
  37. Int J Mol Med. 2014 May;33(5):1364-70 - PubMed
  38. Cell Mol Life Sci. 2018 Sep;75(18):3313-3327 - PubMed
  39. Expert Opin Pharmacother. 2019 Apr;20(6):691-699 - PubMed
  40. Int J Mol Sci. 2020 May 27;21(11): - PubMed
  41. Rev Endocr Metab Disord. 2008 Dec;9(4):329-43 - PubMed
  42. Br J Pharmacol. 2015 Aug;172(15):3793-804 - PubMed
  43. Acta Med Scand. 1988;223(1):79-82 - PubMed
  44. Transl Psychiatry. 2012 Feb 21;2:e79 - PubMed
  45. Am J Psychiatry. 1987 Sep;144(9):1220-1 - PubMed
  46. J Endocrinol. 2013 Aug 28;218(3):R25-36 - PubMed
  47. Sci Rep. 2020 Feb 14;10(1):2671 - PubMed
  48. Ren Fail. 2014 Apr;36(3):419-31 - PubMed
  49. J Clin Med. 2020 Aug 10;9(8): - PubMed
  50. Sci Rep. 2020 Jun 19;10(1):9985 - PubMed
  51. Int J Clin Exp Pathol. 2010 Mar 25;3(5):505-14 - PubMed
  52. Chemosphere. 2019 Feb;217:516-521 - PubMed
  53. J Am Acad Child Adolesc Psychiatry. 2013 Aug;52(8):784-96 - PubMed
  54. Molecules. 2020 Apr 03;25(7): - PubMed
  55. Immunol Cell Biol. 2020 Jan;98(1):54-66 - PubMed
  56. Sci Rep. 2020 Oct 1;10(1):16360 - PubMed
  57. Psychiatry Res. 2015 Sep 30;229(1-2):257-63 - PubMed
  58. BMC Pharmacol Toxicol. 2016 Dec 14;17(1):59 - PubMed
  59. Psychosomatics. 2014 Mar-Apr;55(2):163-71 - PubMed
  60. Clin Chim Acta. 2019 Nov;498:30-37 - PubMed
  61. J Pharm Pharmacol. 1999 Jun;51(6):741-3 - PubMed
  62. Res Pharm Sci. 2015 Sep-Oct;10(5):460-5 - PubMed
  63. Int J Mol Sci. 2021 Jan 02;22(1): - PubMed
  64. Aust Prescr. 2021 Feb;44(1):12-15 - PubMed
  65. BMB Rep. 2008 Oct 31;41(10):710-5 - PubMed
  66. Diabetes. 2020 Jun;69(6):1126-1139 - PubMed
  67. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:32-45 - PubMed
  68. Neuropsychiatr Dis Treat. 2019 Jul 22;15:2087-2099 - PubMed
  69. J Trace Elem Med Biol. 2017 Dec;44:315-321 - PubMed
  70. Clin Exp Pharmacol Physiol. 2011 Jan;38(1):1-10 - PubMed
  71. Psychother Psychosom. 2018;87(2):65-74 - PubMed
  72. Turk J Pharm Sci. 2020 Jun;17(3):293-298 - PubMed
  73. Pharmacol Res Perspect. 2021 Apr;9(2):e00732 - PubMed
  74. J Clin Pharm Ther. 2019 Apr;44(2):327-334 - PubMed
  75. Eur J Gastroenterol Hepatol. 1995 Apr;7(4):373-6 - PubMed
  76. Int Clin Psychopharmacol. 2021 Jan;36(1):34-37 - PubMed
  77. Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):336-44 - PubMed
  78. J Pharmacol Sci. 2009 Apr;109(4):496-503 - PubMed
  79. Biomed Pharmacother. 2018 Oct;106:381-389 - PubMed

Publication Types